G1 Therapeutics, Inc. reaffirmed earnings guidance for the full year 2024. The company expects to generate between $60 million and $70 million in COSELA net revenue in 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.28 USD | +1.33% |
|
-8.06% | -25.25% |
25/06 | Needham Lowers Price Target on G1 Therapeutics to $6 From $12, Maintains Buy Rating | MT |
25/06 | HC Wainwright Lowers G1 Therapeutics Price Target to $3 From $9, Maintains Buy Rating | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-25.25% | 12Cr | |
+15.20% | 12TCr | |
+19.67% | 11TCr | |
+18.95% | 2.6TCr | |
-23.86% | 1.94TCr | |
-19.03% | 1.59TCr | |
-20.90% | 1.51TCr | |
-46.14% | 1.51TCr | |
+63.85% | 1.49TCr | |
+4.49% | 1.39TCr |
- Stock Market
- Equities
- GTHX Stock
- News G1 Therapeutics, Inc.
- G1 Therapeutics, Inc. Reaffirms Earnings Guidance for the Full Year 2024